Table 2.
Concordance between drug combinatory effect in experiment and the concordance ratio
| Data sets | Cancer type | Drug combination | Drug interaction affection in biology experience | Differential expressed genes by the combinatory effect of two drugs (A) | The genes number of the same variation direction (B) | Concordance ratio (C) |
|---|---|---|---|---|---|---|
| GSE45587 | Neuroblastoma | All-trans retinoic acid & valproic acid | The treatment of valproic acid is augmented by all-trans retinoic acid (Additive) | 6965 | 3212 | 0.46 |
| GSE11550 | Melanoma | Elesclomol & paclitaxel | Drug combination has significant effect in cancer (Additive) | 5578 | 1903 | 0.34 |
| GSE43452 | Glioblastoma | Temozolomide & Y.15 (FAK inhibitor) | Combination can significantly reduce tumor growth (Additive) | 6479 | 3249 | 0.50 |
| GSE33366 | Breast cancer | Tamoxifen & BMS754807 | Synergy | 5191 | 2664 | 0.51 |
| GSE33366 | Breast cancer | Letrozole & BMS754807 | Synergy | 3440 | 1843 | 0.54 |
| GSE6914 | Nonsmall cell lung cancer | Bexarotene & gemcitabine | Resensitized (Sysnergy) | 4587 | 3368 | 0.73 |